Literature DB >> 20729468

Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome.

Benjamin Terrier1, Ivan Bièche, Thierry Maisonobe, Ingrid Laurendeau, Michèlle Rosenzwajg, Jean-Emmanuel Kahn, Marie-Claude Diemert, Lucile Musset, Michel Vidaud, Damien Sène, Nathalie Costedoat-Chalumeau, Du Le Thi-Huong, Zahir Amoura, David Klatzmann, Patrice Cacoub, David Saadoun.   

Abstract

Churg-Strauss syndrome (CSS) is characterized by systemic vasculitis and blood and tissue eosinophilia. Blood eosinophilia correlates with disease activity, and activated T cells from CSS patients are predominantly T helper 2 (Th2). Interleukin (IL)-25 has been shown to link innate and adaptive immunity by enhancing Th2 cytokine production. We sought to determine the involvement of IL-25 and its receptor IL-17RB in the pathogenesis of CSS. We found increased levels of IL-25 in the serum of active CSS patients (952 ± 697 vs 75 ± 49 pg/mL in inactive patients and 47 ± 6 pg/mL in healthy donors). IL-25 was correlated with disease activity and eosinophil level. Eosinophils were the main source of IL-25, whereas activated CD4(+) memory T cells were the IL-17RB-expressing cells in CSS. IL-25 enhanced the production of IL-4, IL-5, and IL-13 by activated peripheral blood mononuclear cells. IL-25 and IL-17RB were observed within the vasculitic lesions of patients with CSS, and IL-17RB colocalized with T cells. Increased expression of IL-17RB, tumor necrosis factor receptor-associated factor 6, and JunB in vasculitic lesions of CSS underscored the IL-25-mediated activation, whereas up-regulation of GATA3 and IL-10 supported Th2 differentiation. Our findings suggest that eosinophils, through the production of IL-25, exert a critical role in promoting Th2 responses in target tissues of CSS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20729468     DOI: 10.1182/blood-2010-02-267542

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Innate immune cells in the pathogenesis of primary systemic vasculitis.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

4.  IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary disease.

Authors:  Bryan C Petersen; Vladislav Dolgachev; Andrew Rasky; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2014-01-09       Impact factor: 4.962

5.  IL-17RB+ granulocytes are associated with airflow obstruction in asthma.

Authors:  Lin Li; Nicholas W Lukacs; Matthew A Schaller; Bryan Petersen; Alan P Baptist
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

6.  Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

Authors:  Peter C Grayson; Paul A Monach; Christian Pagnoux; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

Review 7.  Churg-strauss syndrome: an update.

Authors:  Andy Abril
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

8.  Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Shigeki Katoh; Masaki Ikeda; Nobuhiro Matsumoto; Hiroki Shimizu; Masaaki Abe; Yoshihiro Ohue; Keiji Mouri; Yoshihiro Kobashi; Masamitsu Nakazato; Mikio Oka
Journal:  Lung       Date:  2017-09-05       Impact factor: 2.584

Review 9.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.